Heartflow, Inc. (HTFL) stock analysis

Healthcare · Health Information Services

From the 10-K filed 2026-03-18

What protects it: the moat

It maintains a dataset of 160 million annotated CCTA images used to refine AI algorithms through a proprietary human-in-the-loop quality control process.

The company is shielded by a 10-year lead in algorithm development, fueled by a proprietary dataset of 160 million annotated images. It utilizes a human-in-the-loop production process where dedicated analysts review and correct AI-generated 3D heart models.

These corrections are stored and used as labels to train future generations of machine learning models. This cycle of continuous refinement creates an accuracy barrier that is difficult for competitors to replicate without similar historical data and human-assisted infrastructure.

What growth costs

It reinvests in its 200 clinical studies to expand indications and employs production analysts to perform quality control on automated CCTA scans.

Growth requires significant spending on large-scale clinical trials to secure guideline inclusion and reimbursement, which is the primary driver of adoption. Beyond R&D, it maintains a capital-efficient commercial model using Territory Sales Managers to acquire new accounts and Territory Account Managers to drive utilization.

Unlike traditional software, it bears direct labor costs for production analysts who must manually inspect every patient case for quality before delivery. Maintaining and growing its 1,465 accounts requires these analysts to scale alongside case volume.

What could damage it

A reversal of AHA and ACC clinical guidelines favoring CCTA could collapse the referral pipeline that its entire platform depends on.

The company is structurally dependent on clinical guidelines issued by the American Heart Association (AHA) and American College of Cardiology (ACC). These current guidelines identify CCTA as a preferred first-line test for coronary artery disease.

If future clinical studies or changes in medical consensus lead these organizations to downgrade CCTA in favor of traditional stress testing, the core input for all its software products would disappear. This would result in a permanent loss of revenue and terminal impairment of its pay-per-click business model.

About Heartflow, Inc.

HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.

Other companies in Health Information Services